Afif Hentati, MD
Neurology · Evanston, ILNPI 1417008483
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,670 of the $189,192 with a category attached, or 74.4%. Biogen accounts for 71.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $49,099 and has fallen 58.2% since, to $20,534 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $965.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$136K
- Amgen$19K
- EMD Serono, Inc.$14K
- Sanofi$8K
- AbbVie$6K
- Novartis$3K
- plus $4K from 8 others
Across 165 payments — averaging $7803.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Banner Life Sciences, LLC$814K
- Genentech, Inc.$167K
- Biogen$105K
- Alkermes, Inc.$72K
- EMD Serono, Inc.$62K
- Roche Products Limited$48K
- plus $20K from 2 others
What the payments were for
- Consulting fees$39,00021%
- Speaking & faculty fees$140,67074%
- Travel & lodging$4,5362%
- Food & beverage$4,8183%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 119 | $135,772 |
| Amgen(2 entities) | 19 | $18,872 |
| EMD Serono, Inc. | 9 | $13,604 |
| Sanofi | 12 | $7,999 |
| AbbVie(2 entities) | 14 | $6,313 |
| Novartis | 8 | $2,556 |
| Genentech, Inc. | 2 | $1,552 |
| Johnson & Johnson | 1 | $1,320 |
| Banner Life Sciences, LLC | 1 | $750 |
| Genentech USA, Inc. | 6 | $258 |
| AstraZeneca | 1 | $122 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$189,192 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZeposiaOzanimod Hydrochloride | 61 | $611,226 |
| TecfideraDimethyl Fumarate | 39 | $427,860 |
| VumerityDiroximel Fumarate | 50 | $389,739 |
| Plegridy PenPeginterferon Beta-1a | 39 | $325,978 |
| CopaxoneGlatiramer Acetate | 49 | $323,845 |
| BetaseronInterferon Beta-1b | 24 | $256,290 |
| EnspryngSatralizumab-Mwge | 12 | $211,267 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $168,020 |
| TysabriNatalizumab | 12 | $97,824 |
| Dimethyl Fumarate | 68 | $85,053 |
| GlatopaGlatiramer Acetate | 23 | $68,173 |
| Glatiramer Acetate | 21 | $45,086 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $42,402 |
| Nurtec OdtRimegepant Sulfate | 22 | $40,548 |
| Dalfampridine ErDalfampridine | 75 | $29,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity, Tysabri | $135,772 | $915,423101 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $13 | $323,84549 claims |
| Genentech USA, Inc.Enspryng | $258 | $211,26712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Evanston
- James VociEvanston$345K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.